What the FDA labels say about taking them together
Insulin lispro and octreotide
Insulin lispro's FDA label of June 4, 2025 names octreotide in its drug interactions section; octreotide's label does not name insulin lispro itself but warns about its class (insulin analogs). The insulin lispro label: “… inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required …”
Check it at the source: the insulin lispro FDA label on DailyMed (effective June 4, 2025, Sanofi-Aventis U.S. LLC); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the insulin lispro label say about octreotide?
Insulin lispro label, drug interactionsDrugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs.
Source: FDA drug label (Insulin Lispro, BLA020563), Eli Lilly and Company, effective June 17, 2025 (SPL set 97d5e596-aae1-42c9-ae89-c3780959c467), via openFDA
Source: FDA drug label (ADMELOG), Sanofi-Aventis U.S. LLC, effective June 4, 2025 (SPL set 0691def8-4a7b-4de3-866f-a280989f47f1), via openFDA; the full label on DailyMed
What does the octreotide label say about insulin lispro?
Octreotide's label does not name insulin lispro itself; it warns about its class (insulin analogs):
Octreotide label, drug interactionsCyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. ( 7 ) Lutetium Lu 177
Octreotide label, drug interactionsOctreotide inhibits the secretion of insulin and glucagon.
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin lispro | Octreotide | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | Diarrhea |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $10.19 per mL 100 unit/mL kwikpen | $2.53 per mL 100 mcg/mL vial |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once